Patients treated with a nasal spray experienced improvement in signs and symptoms of dry eye disease by day 28 of treatment, according to a study.
Michael Raizman, MD, discussed the results of the ONSET-2 phase 3 study of OC-01 (varenicline, Oyster Point Pharma) at the virtual Association for Research in Vision and Ophthalmology meeting.
“OC-01 varenicline, a novel compound delivered via nasal spray, is a highly selective nicotinic acetylcholine receptor agonist that activates the trigeminal parasympathetic pathway that stimulates the lacrimal functional unit to reestablish the natural